Latest News on NUVB

Financial News Based On Company


Advertisement
Advertisement

Nuvation Bio's David Hung: 90% Response Rate in ROS1 Lung Cancer Backs a China-Sourced Drug Strategy

https://finance.biggo.com/news/b50d19af799a7059
David Hung, CEO of Nuvation Bio, discusses the success of obetrosi, a ROS1 lung cancer drug acquired through AnHeart Therapeutics, which boasts a 90% first-line response rate and a median duration of response exceeding four years. Hung emphasizes the drug's efficacy and tolerability, particularly for a younger patient demographic often presenting with brain metastases. Nuvation Bio plans to expand its pipeline through further acquisitions from Chinese labs and academic centers and is developing obetrosi for adjuvant use.

Nuvation Bio reports updated Phase II J201 data for safusidenib

https://www.clinicaltrialsarena.com/news/nuvation-updated-j201-data-safusidenib/
Nuvation Bio has released updated long-term follow-up data from its Phase II J201 trial for safusidenib in patients with IDH1-mutant glioma, showing an 81.5% centrally assessed confirmed clinical benefit rate and a 51.9% objective response rate. The drug demonstrated a manageable safety profile with mostly low-grade adverse events and achieved US FDA fast track designation in August 2026. These results support its continued evaluation in the pivotal Phase III SIGMA study.

Nuvation Bio reports updated Phase II J201 data for safusidenib

https://www.yahoo.com/news/science/articles/nuvation-bio-reports-updated-phase-111507977.html
Nuvation Bio has released updated long-term follow-up results from its Phase II J201 trial for safusidenib, an oral treatment for IDH1-mutant glioma. The data, presented at a neuro-oncology meeting, demonstrated an 81.5% confirmed clinical benefit rate and a 51.9% objective response rate. The therapy, which received FDA fast track status in August 2026, is now progressing to a pivotal Phase III SIGMA study.

Nuvation Bio stock hits 52-week low at 3.91 USD By Investing.com

https://ca.investing.com/news/stock-market-news/nuvation-bio-stock-hits-52week-low-at-391-usd-93CH-4961394
Nuvation Bio Inc. (NUVB) stock has hit a 52-week low of $3.91, reflecting a 55% year-to-date decline and a 14.56% decrease over the past year. Despite this downturn, analysts maintain optimistic price targets ranging from $7 to $21. The company recently reported third-quarter revenue of $44.95 million, exceeding expectations, primarily due to strong sales of its cancer drug IBTROZI, though it still reported a loss of $0.12 per share.

Nuvation Bio stock hits 52-week low at 3.91 USD By Investing.com

https://uk.investing.com/news/stock-market-news/nuvation-bio-stock-hits-52week-low-at-391-usd-93CH-4985394
Nuvation Bio Inc.'s stock (NUVB) recently hit a 52-week low of $3.91, currently trading at $3.92, representing a 55% year-to-date decline and a 14.56% decrease over the past year. Despite this downturn and stock volatility (beta of 1.73), analysts maintain optimistic price targets ranging from $7 to $21. The company recently surpassed Q3 revenue expectations, driven by its cancer drug IBTROZI, but reported a loss per share that aligned with forecasts, with ongoing losses and challenges in the rare-disease market potentially contributing to investor concerns.
Advertisement

Nuvation Bio presents long-term data on brain cancer drug

https://www.investing.com/news/company-news/nuvation-bio-presents-longterm-data-on-brain-cancer-drug-93CH-5029839
Nuvation Bio Inc. (NYSE:NUVB) presented positive long-term follow-up data from a Phase 2 study of its brain cancer drug, safusidenib, for patients with grade 2 IDH1-mutant glioma. The study showed an 81.5% clinical benefit rate and a 51.9% objective response rate in chemotherapy- and radiotherapy-naïve patients, with most remaining on treatment for over 36 months. The company is now conducting a Phase 3 study and safusidenib has received Fast Track designation from the FDA.

With $27.5M in U.S. IBTROZI sales, Nuvation Bio (NUVB) narrows its quarterly loss.

https://www.stocktitan.net/sec-filings/NUVB/8-k-nuvation-bio-inc-reports-material-event-daa58059f3f8.html
Nuvation Bio (NUVB) reported a significant increase in total revenue to $44.951 million for Q3 2026, up from $13.120 million in Q3 2025, largely driven by $27.457 million in U.S. IBTROZI sales. The company narrowed its net loss to $41.899 million ($0.12 per share) from $55.792 million ($0.16 per share) in the prior year. Key highlights include the FDA's approval of an sNDA for IBTROZI, reflecting a 49.7-month median duration of response, and Fast Track Designation for safusidenib for IDH1-mutant glioma, along with a strong cash position of $663.4 million.

Form 8K Nuvation Bio Inc For: 4 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-nuvation-bio-inc-for-4-november-93CH-2783985
This article from Investing.com announces that Nuvation Bio Inc. filed a Form 8K on November 4th. The brief news item includes the stock ticker NUVB and a mention of its daily performance, indicating a routine financial disclosure by the company.

Form 8K Nuvation Bio Inc For: 4 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-nuvation-bio-inc-for-4-november-93CH-4958429
This article from Investing.com announces that Nuvation Bio Inc. filed a Form 8K on November 4th. The filing is a standard requirement for public companies to disclose significant events that shareholders should know about. No specific details about the content of the 8K filing are provided within this brief notice.

Nuvation Bio (NUVB) Stock Price, Chart & Analysis

https://www.debelegger.nl/en/stock/NUVB.US
This article provides a detailed analysis of Nuvation Bio (NUVB) stock, including its latest price, market listing, key financial figures, and a "Belegger score." It highlights that Nuvation Bio does not pay a dividend and has strong revenue growth but negative net margins. The analysis also covers valuation metrics, balance sheet strength, and a "what if" scenario for future price targets.
Advertisement

Nuvation Bio, Inc. Class A Estimates – FWB:1E30

https://www.tradingview.com/symbols/FWB-1E30/financials-estimates/
This article provides an overview of Nuvation Bio, Inc. Class A (FWB:1E30) on the Frankfurt Stock Exchange through TradingView. It details the availability of financial actuals and analyst estimates across various financial statements and valuation metrics. Users can explore reported financial data, compare it with average, high, and low estimates, and visualize trends over time.

NUVB: IBTROZI dominates ROS1 with best-in-class efficacy, while safusidenib advances across glioma subtypes

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4152065:0-nuvb-ibtrozi-dominates-ros1-with-best-in-class-efficacy-while-safusidenib-advances-across-glioma-subtypes/
Nuvation Bio Inc. (NUVB) is highlighted for its leading drug IBTROZI, which shows unmatched efficacy and safety in the ROS1 market, contributing to rapid adoption and revenue potential. Additionally, safusidenib is advancing with promising results across all glioma subtypes, supported by multiple ongoing trials. The company's continued growth is underpinned by robust cash reserves and a disciplined approach to business development.

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer

https://www.prnewswire.com/news-releases/nuvation-bio-announces-new-analyses-reinforcing-the-durable-consistent-efficacy-of-ibtrozi-taletrectinib-across-key-patient-subgroups-in-advanced-ros1-nsclc-at-2026-world-conference-on-lung-cancer-302877991.html
Nuvation Bio Inc. announced new subgroup analyses from its pivotal TRUST-I and TRUST-II studies at the IASLC 2026 World Conference on Lung Cancer, demonstrating the consistent efficacy of IBTROZI® (taletrectinib) in advanced ROS1+ non-small cell lung cancer (NSCLC). The data showed IBTROZI maintained high response rates and durable responses regardless of prior chemotherapy exposure or ROS1 fusion partner. These findings reinforce IBTROZI's utility across various patient subgroups and highlight the importance of early biomarker testing.

Nuvation Bio (NUVB) CSO sells 100K shares at $7.09

https://www.stocktitan.net/sec-filings/NUVB/form-4-nuvation-bio-inc-insider-trading-activity-3bd0622b55b8.html
Nuvation Bio Inc.'s Chief Scientific Officer, Gary Hattersley, exercised options for 100,000 shares of Class A Common Stock at $1.87 per share and subsequently sold all 100,000 shares at a weighted-average price of $7.0924. This transaction, executed on August 19, 2026, was part of a Rule 10b5-1 trading plan established on December 4, 2025. After the exercise and sale, Hattersley directly holds 400,000 stock options, with the exercised option vesting schedule detailed for future equity.

Nuvation Bio (NYSE: NUVB) posts $31.7M Q2 revenue and $62.8M loss

https://www.stocktitan.net/sec-filings/NUVB/8-k-nuvation-bio-inc-reports-material-event-afc8141ed78b.html
Nuvation Bio (NYSE: NUVB) announced Q2 2026 revenue of $31.7 million, driven by strong sales of its ROS1 inhibitor IBTROZI and collaboration agreements, representing a significant increase from the previous year. Despite the revenue growth, the company reported a net loss of $62.8 million due to high research and development and administrative expenses. Nuvation Bio also provided updates on its clinical pipeline, including positive Phase 2 data for safusidenib and strategic financial moves to strengthen its balance sheet.
Advertisement

Nuvation Bio (NUVB) Corporate presentation Summary

https://quartr.com/events/nuvation-bio-inc-nuvb-corporate-presentation_FL4uRarH
Nuvation Bio (NUVB) presented a corporate summary highlighting its focus on oncology medicines and strong financial position. The company emphasized the success of IBTROZI (taletrectinib), approved for advanced ROS1+ NSCLC, noting its high efficacy, favorable safety profile, and significant market potential. The presentation also touched upon a robust pipeline and accelerating adoption of first-line oncology drugs.

Nuvation Bio (NUVB) raises $287.5M in 0.75% convertible notes with greenshoe

https://www.stocktitan.net/sec-filings/NUVB/8-k-nuvation-bio-inc-reports-material-event-87fd4b179b71.html
Nuvation Bio Inc. has successfully closed a registered underwritten offering, raising $287.5 million through 0.75% Convertible Senior Notes due 2032, which included a $37.5 million greenshoe option exercised by underwriters. The company expects net proceeds of approximately $277.6 million, with a portion used for capped call transactions to mitigate dilution. The remaining funds are allocated for general corporate purposes, including working capital and operating expenses.

The Status of Nuvation Bio’s Pipeline

https://www.pharmexec.com/view/status-nuvation-bio-pipeline
Nuvation Bio’s CEO, David Hung, discusses the company's oncology pipeline, highlighting the successful launch of Ibtrozi for ROS1-positive non-small cell lung cancer and its development in earlier stages. He also details the promising results of safusidenib in both high- and low-grade brain tumors, including glioblastoma, emphasizing its efficacy and tolerability. The company aims to advance both drugs through pivotal studies and expand their indications.

Nuvation Bio Inc. Class A (NUVB) Stock Price | Live Quotes & Charts | NYSE

https://timothysykes.com/quote/NUVB/
This page provides live quotes and charts for Nuvation Bio Inc. Class A (NUVB) stock, showing its current price of $6.11, an increase of $0.24 (4.09%). It indicates that analyst ratings and earnings information for NUVB are not currently available. The page also includes disclaimers about the risks of stock trading and statistics suggesting that most day traders lose money.

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

https://sg.finance.yahoo.com/news/nuvation-bio-inc-announces-full-210900758.html
Nuvation Bio Inc. announced that the underwriters have fully exercised their over-allotment option, or "Greenshoe Exercise," to purchase an additional $37.5 million of its 0.75% Convertible Senior Notes due 2032. This brings the total offering to $287.5 million. The net proceeds, estimated at $277.6 million, will be used for general corporate purposes, including working capital and operational expenses, after covering the cost of additional capped call transactions.
Advertisement

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

https://www.tradingview.com/news/prnewswire:83d2234f663b9:0-nuvation-bio-inc-announces-full-exercise-of-greenshoe-option-in-287-5-million-convertible-senior-notes-offering/
Nuvation Bio Inc. announced the full exercise of its underwriters' over-allotment option (Greenshoe Exercise) to purchase an additional $37.5 million in 0.75% Convertible Senior Notes due 2032, bringing the total offering to $287.5 million. The net proceeds of approximately $277.6 million, after deductions, will be used to cover the cost of additional capped call transactions and for general corporate purposes. This offering was conducted following a registration statement filed with the SEC.

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

https://www.prnewswire.com/news-releases/nuvation-bio-inc-announces-full-exercise-of-greenshoe-option-in-287-5-million-convertible-senior-notes-offering-302818744.html
Nuvation Bio Inc. announced that the underwriters have fully exercised their over-allotment option, or "Greenshoe Exercise," to purchase an additional $37.5 million in convertible senior notes due 2032. This brings the total aggregate principal amount of notes sold in the offering to $287.5 million. The net proceeds from the offering are estimated at approximately $277.6 million, which will be used for general corporate purposes and to cover the cost of additional capped call transactions.

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

https://investingnews.com/nuvation-bio-inc-announces-full-exercise-of-greenshoe-option-in-287-5-million-convertible-senior-notes-offering/
Nuvation Bio Inc. announced that the underwriters fully exercised their over-allotment option to purchase an additional $37.5 million in convertible senior notes, bringing the total offering to $287.5 million. The company entered into additional capped call transactions and expects net proceeds of approximately $277.6 million, which will be used for the capped call costs and general corporate purposes. This offering is part of Nuvation Bio's strategy to fund its oncology drug development pipeline.

Total common shares outstanding of Nuvation Bio, Inc. Class A – FWB:1E30

https://www.tradingview.com/symbols/FWB-1E30/financials-statistics-and-ratios/total-shares-outstanding/
This article provides details on the total common shares outstanding for Nuvation Bio, Inc. Class A, traded on the Frankfurt Stock Exchange under the ticker FWB:1E30. It indicates that the market was closed with no trades when the information was accessed. The page also features an overview for this specific stock, noting its category under biotechnology within health technology.

Price to earnings forward of Nuvation Bio, Inc. Class A – FWB:1E30

https://www.tradingview.com/symbols/FWB-1E30/financials-statistics-and-ratios/price-earnings-fwd/
This article provides financial information for Nuvation Bio, Inc. Class A (FWB:1E30) on the Frankfurt Stock Exchange. It specifically highlights the "Price to earnings forward" metric for the company. The page appears to be a financial data presentation without detailed analysis.
Advertisement

ETFs Investing in Nuvation Bio, Inc. Class A Stocks

https://www.tradingview.com/symbols/FWB-1E30/etfs/
This article lists various Exchange Traded Funds (ETFs) that hold Nuvation Bio, Inc. Class A stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover different investment focuses including small-cap, health care, biotechnology, micro-cap, and ESG, offering diverse options for investors interested in Nuvation Bio.

Nuvation Bio Issues Convertible Notes, Retires Secured Debt

https://www.theglobeandmail.com/investing/markets/stocks/NUVB/pressreleases/3087332/nuvation-bio-issues-convertible-notes-retires-secured-debt/
Nuvation Bio (NUVB) recently completed a public offering of $250 million in 0.75% Convertible Senior Notes due 2032, allowing the company to retire approximately $58.5 million of existing secured debt. This move reshapes Nuvation Bio's capital structure, replacing secured debt with longer-dated convertible notes, which could ease short-term balance sheet pressure but introduces potential future equity dilution risk for shareholders. Analysts have a "Buy" rating on NUVB stock with an $11.00 price target, though TipRanks' AI Analyst Spark rates it "Neutral" due to large losses despite revenue growth.

Nuvation Bio (NUVB) Jefferies Global Healthcare Conference 2026 Summary

https://quartr.com/events/nuvation-bio-inc-nuvb-jefferies-global-healthcare-conference-2026_FL4uRoZR
Nuvation Bio (NUVB) presented at the Jefferies Global Healthcare Conference 2026, highlighting the strong performance of its drug IBTROZI, which leads the ROS1 market with high response rates and durable efficacy, benefiting from recent NCCN guideline changes. The company also discussed its pipeline, including safusidenib for IDH1 mutant glioma with data expected in 2027, and the ongoing TRUST-IV study for IBTROZI in earlier-stage disease. The presentation emphasized market growth driven by increased molecular testing and the long-term potential of their chronic disease therapies.

Nuvation Bio, Inc. Class A Actuals & Estimates (NYSE:NUVB)

https://www.tradingview.com/symbols/NYSE-NUVB/forecast-actuals-and-estimates/
This article provides an overview of Nuvation Bio Inc. (NYSE: NUVB) stock performance, financial estimates, and analyst forecasts. It covers key metrics like current stock price, historical highs and lows, market capitalization, volatility, and details on past and upcoming earnings reports, including revenue and net income figures.

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

https://www.prnewswire.com/news-releases/nuvation-bio-announces-pricing-of-upsized-offering-of-250-0-million-of-convertible-senior-notes-302811504.html
Nuvation Bio Inc. has announced the pricing of an upsized underwritten offering of $250.0 million in 0.75% Convertible Senior Notes due in 2032. The net proceeds, estimated at approximately $241.2 million, will be used to pay for capped call transactions, repay a senior secured loan agreement, and for general corporate purposes. The offering includes an option for underwriters to purchase an additional $37.5 million in notes to cover over-allotments.
Advertisement

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

https://www.newportvermontdailyexpress.com/online_features/press_releases/nuvation-bio-announces-pricing-of-upsized-offering-of-250-0-million-of-convertible-senior-notes/article_e7857e86-7ca7-5433-a54e-492c13685010.html
Nuvation Bio Inc. (NYSE: NUVB) announced the pricing of an upsized underwritten offering of $250.0 million in 0.75% Convertible Senior Notes due 2032, an increase from the initial $200.0 million. The company expects net proceeds of approximately $241.2 million, which will be used to fund capped call transactions, repay obligations under its senior secured loan agreement, and for general corporate purposes. The Notes will mature on July 1, 2032, and are convertible into cash, Class A common stock, or a combination thereof, with an initial conversion price of $7.84 per share.

Nuvation Bio Announces Proposed Convertible Senior Notes Offering

https://investingnews.com/nuvation-bio-announces-proposed-convertible-senior-notes-offering/
Nuvation Bio Inc. announced its intent to offer $200.0 million in Convertible Senior Notes due in 2032, with an option for underwriters to purchase an additional $30.0 million. The company plans to use the proceeds to cover capped call transactions, repay its senior secured loan, and for general corporate purposes. The offering is subject to market conditions, and the notes will be unsecured obligations, maturing on July 1, 2032.

Nuvation Bio’s chief people officer sells $753k in stock

https://m.investing.com/news/insider-trading-news/nuvation-bios-chief-people-officer-sells-753k-in-stock-93CH-4759410?ampMode=1
Nuvation Bio's Chief People Officer, Markel Stacy, sold 125,000 shares of Class A Common Stock for $753,187, following the exercise of stock options. This sale was part of a pre-arranged trading plan, occurring after the company's stock surged 215% over the past year. Nuvation Bio also reported strong Q1 2026 earnings, announced a partnership with Thermo Fisher Scientific, and presented positive data from its TRUST-II study.

Nuvation Bio prices $250M convertible notes offering

https://www.investing.com/news/company-news/nuvation-bio-prices-250m-convertible-notes-offering-93CH-4761987
Nuvation Bio Inc. has priced an upsized offering of $250 million in convertible senior notes due in 2032, increasing from a previously announced $200 million. The biotech company will use the proceeds to pay for capped call transactions, repay its existing senior secured loan of $217 million, and fund general corporate purposes. Despite being unprofitable, Nuvation Bio boasts significant revenue growth and strong liquidity.

Nuvation Bio Announces Proposed Convertible Senior Notes Offering

https://www.tradingview.com/news/prnewswire:c63c8ee8cd2f9:0-nuvation-bio-announces-proposed-convertible-senior-notes-offering/
Nuvation Bio (NUVB) has announced a proposed underwritten offering of $200.0 million in Convertible Senior Notes due in 2032, with an option for underwriters to purchase an additional $30.0 million. The company plans to use the net proceeds to cover capped call transactions, repay a senior secured loan, and for general corporate purposes. This offering is intended to manage potential stock dilution and financial obligations.
Advertisement

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

https://investingnews.com/nuvation-bio-announces-pricing-of-upsized-offering-of-250-0-million-of-convertible-senior-notes/
Nuvation Bio Inc. (NYSE: NUVB) announced the pricing of an upsized underwritten offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032, increasing from the previously announced $200.0 million. The company expects net proceeds of approximately $241.2 million, which will be used to pay for capped call transactions, repay its senior secured loan agreement, and for general corporate purposes. Noteholders can convert the Notes under specific conditions, and Nuvation Bio may redeem them after July 6, 2029, under certain stock price conditions.

Nuvation Bio CFO Sauvage sells $286k in stock

https://www.investing.com/news/insider-trading-news/nuvation-bio-cfo-sauvage-sells-286k-in-stock-93CH-4759391
Nuvation Bio's CFO, Philippe Sauvage, sold 47,668 shares of Class A Common Stock for $286,370 on June 23, 2026, as part of a pre-arranged trading plan. This transaction occurred after he exercised stock options to acquire the shares. Following the sale, Sauvage holds 12,673 direct shares and 702,332 derivative securities in the company.

Nuvation Bio CFO Sauvage sells $286k in stock

https://m.uk.investing.com/news/stock-market-news/nuvation-bio-cfo-sauvage-sells-286k-in-stock-93CH-4743424?ampMode=1
Nuvation Bio's CFO, Philippe Sauvage, sold 47,668 shares of Class A Common Stock for $286,370 on June 23, 2026, after exercising stock options. This sale was pre-arranged under a 10b5-1 plan, and comes amidst the company's stock surging 215% over the past year, though an InvestingPro analysis suggests it might be overvalued. Nuvation Bio also recently reported strong Q1 2026 earnings and positive developments for its drug IBTROZI.

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

https://www.hazard-herald.com/online_features/press_releases/nuvation-bio-announces-pricing-of-upsized-offering-of-250-0-million-of-convertible-senior-notes/article_cb1d5b83-d12c-50e4-bcb1-d4a0a17c9ad0.html
Nuvation Bio Inc. announced the pricing of an upsized underwritten offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032, an increase from the previously announced $200.0 million. The company expects net proceeds of approximately $241.2 million, which will be used to pay for capped call transactions, repay its senior secured loan agreement, and for general corporate purposes. The notes will mature on July 1, 2032, and are convertible into cash, Class A common stock, or a combination thereof, at Nuvation Bio's election, with an initial conversion rate of 127.4941 shares per $1,000 principal amount.

Nuvation Bio stock tumbles on $200M convertible notes offering

https://www.investing.com/news/stock-market-news/nuvation-bio-stock-tumbles-on-200m-convertible-notes-offering-93CH-4760662
Nuvation Bio Inc. (NYSE:NUVB) shares dropped 11.8% in premarket trading after the oncology company announced a plan to offer $200 million in convertible senior notes due 2032. The company will use the proceeds to pay for capped call transactions, repay existing senior secured loan obligations, and for general corporate purposes. Jefferies LLC, Citigroup, and Cantor Fitzgerald & Co. are serving as joint bookrunning managers for the offering.
Advertisement

Nuvation Bio CFO Sauvage sells $286k in stock By Investing.com

https://m.au.investing.com/news/stock-market-news/nuvation-bio-cfo-sauvage-sells-286k-in-stock-93CH-4503569?ampMode=1
Nuvation Bio Inc.'s CFO, Philippe Sauvage, sold 47,668 shares of Class A Common Stock for $286,370 on June 23, 2026, as part of a pre-arranged trading plan, after exercising stock options. Despite a significant stock surge, InvestingPro suggests the shares might be overvalued. The company recently reported strong Q1 2026 earnings, completed a technology transfer for IBTROZI manufacturing, and received an "Outperform" rating from RBC Capital.

Nuvation Bio chief regulatory officer sells $379k in stock

https://m.investing.com/news/insider-trading-news/nuvation-bio-chief-regulatory-officer-sells-379k-in-stock-93CH-4759395?ampMode=1
Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc. (NASDAQ:NUVB), sold 63,000 shares of company stock worth $379,190 on June 23, 2026, following the exercise of stock options. This sale was conducted under a 10b5-1 trading plan and comes after a significant 215% surge in Nuvation Bio's stock over the past year. The transaction reduced Wentworth's direct holdings to 53,000 shares, while the company has recently reported strong first-quarter 2026 earnings and positive developments in its clinical trials and manufacturing.

Nuvation Bio chief regulatory officer sells $379k in stock

https://www.investing.com/news/insider-trading-news/nuvation-bio-chief-regulatory-officer-sells-379k-in-stock-93CH-4759395
Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc. (NASDAQ:NUVB), sold 63,000 shares of the company’s Class A Common Stock for approximately $379,190 on June 23, 2026, following the exercise of stock options. The sale was executed via a 10b5-1 trading plan. This transaction occurred after Nuvation Bio's stock surged 215% over the past year, though InvestingPro suggests it may be overvalued relative to its Fair Value.

Nuvation Bio director Robert Mashal buys $118,250 in stock

https://www.investing.com/news/insider-trading-news/nuvation-bio-director-robert-mashal-buys-118250-in-stock-93CH-4738706
Robert Mashal, a director at Nuvation Bio Inc. (NASDAQ:NUVB), recently purchased 25,000 shares of the company’s Class A Common Stock for $118,250 through his revocable trust. This transaction increases his indirect ownership to 225,000 shares. The purchase comes as InvestingPro analysis suggests the stock is undervalued, having delivered a 163% return over the past year.

Nuvation Bio director Robert Mashal buys $118,250 in stock

https://m.investing.com/news/insider-trading-news/nuvation-bio-director-robert-mashal-buys-118250-in-stock-93CH-4738706?ampMode=1
Nuvation Bio Inc. director Robert Mashal recently purchased 25,000 shares of the company's Class A Common Stock for $118,250, increasing his indirect ownership to 225,000 shares. This transaction occurred amidst positive news for Nuvation Bio, including strong Q1 2026 earnings, a manufacturing partnership with Thermo Fisher Scientific for IBTROZI, and promising patient-reported outcomes from the TRUST-II study. RBC Capital has reiterated an Outperform rating with a $20.00 price target, highlighting the continued value in the ROS1 market.
Advertisement

Nuvation Bio (NUVB) director’s trust buys 25,000 Class A shares

https://www.stocktitan.net/sec-filings/NUVB/form-4-nuvation-bio-inc-insider-trading-activity-e33ac05134c3.html
Nuvation Bio director Robert Mashal, through his revocable trust, purchased 25,000 shares of Class A Common Stock at $4.73 per share in an open-market transaction. This acquisition increases the trust's total holdings to 225,000 shares of Nuvation Bio Class A Common Stock. The transaction is detailed in a Form 4 SEC filing, indicating a positive sentiment for the company.

Nuvation Bio (NUVB) shareholders elect directors, ratify KPMG and approve pay

https://www.stocktitan.net/sec-filings/NUVB/8-k-nuvation-bio-inc-reports-material-event-d1aee89d2c0a.html
Nuvation Bio Inc. (NUVB) announced the results of its 2026 Annual Meeting. Shareholders elected Class A directors Robert B. Bazemore, Jr. and Robert Mashal, M.D., and Class B director Kim Blickenstaff, to serve until the 2029 annual meeting. Additionally, KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and executive compensation was approved on an advisory basis.

Nuvation Bio Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results

https://www.minichart.com.sg/2026/05/28/nuvation-bio-inc-files-form-8-k-with-sec-detailing-company-information-and-annual-meeting-results/
Nuvation Bio Inc. filed an 8-K form with the SEC, detailing the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Key outcomes included the election of directors, ratification of KPMG LLP as auditor, and an advisory vote on executive compensation. The report also noted the company's transition out of "emerging growth company" status.

Nuvation Bio Inc. (NUVB) director awarded 76,923 stock options in corrected filing

https://www.stocktitan.net/sec-filings/NUVB/form-4-a-nuvation-bio-inc-amended-insider-trading-activity-f55e98598bfa.html
Nuvation Bio Inc. director Xiangmin Cui's insider trading report has been corrected through an amended Form 4 filing, revealing he was granted 76,923 stock options for Class A common stock on February 27, 2026. This rectifies an administrative error in a previous filing that reported 74,813 options. The options have an exercise price of $5.91 and vest over 24 months, starting January 1, 2026.

Nuvation Bio (NUVB) director Cui receives 123,397 stock options expiring 2036

https://www.stocktitan.net/sec-filings/NUVB/form-4-nuvation-bio-inc-insider-trading-activity-2f2714f8cd0c.html
Nuvation Bio (NUVB) director Xiangmin Cui was granted 123,397 stock options with an exercise price of $4.79 per share, expiring on May 20, 2036. These options represent a compensation-related acquisition and will fully vest on the earlier of May 21, 2026, or the next shareholder annual meeting, contingent on Cui's continuous service. This transaction increases Cui's derivative holdings in the company.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement